At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Eligard (TM)drug
Likely dose
Eligard (TM) 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer
In Brief
A Phase 4 clinical trial evaluating Eligard (TM) for Prostate Cancer. Completed, enrolled 42 participants.
Detailed Summary
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
Countries--
CollaboratorsSanofi-Synthelabo
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2003
Primary CompletionJun 2009
First PostedJun 2010
TodayJul 2026
First PostedJun 3, 2010
Enrollment StartOct 1, 2003
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 16.1 years ago
Interventions
Eligard (TM)drug
Eligard (TM) 22.5 mg administered at baseline and Month 3